For Doctors in a Hurry
- Clinicians lack data on whether frequent botulinum toxin injections cause irreversible muscle paralysis or long-term physiological changes.
- The study followed 21 women receiving 20 units of onabotulinum toxin A every 6, 9, or 12 weeks for 156 weeks.
- Electromyography confirmed sustained muscle suppression through 156 weeks, with activity remaining significantly below pretreatment baseline levels across all groups.
- The researchers concluded that prolonged intermittent toxin administration produces a durable chemodenervation effect that persists even after treatment cessation.
- Physicians should note that frequent dosing maintains muscle inactivity, though larger studies are required to confirm these long-term safety findings.
The Physiological Limits of Botulinum Chemodenervation
Botulinum neurotoxin A has become a cornerstone of both aesthetic medicine and the treatment of various therapeutic conditions, ranging from chronic migraine to major depressive disorder [1, 2, 3]. Meta-analytic data involving 417 participants indicates that the toxin exerts a significant effect on depressive symptoms with a Hedges’ g of -0.82 (95% CI, -1.38 to -0.27), suggesting a substantial clinical impact [1]. While its efficacy in reducing glabellar line severity is well-established, the standard clinical effect typically wanes within three to four months, though higher dosages, such as 40 units of prabotulinumtoxinA-xvfs, have demonstrated a median duration of 183 days [4, 5]. Clinicians frequently encounter questions regarding whether repeated exposure might lead to secondary treatment failure (the loss of clinical response in a previously responsive patient) or the formation of neutralizing antibodies (immune proteins that block the toxin’s biological activity), though recent data involving nearly 30,000 subject records show the rate of antibody formation is low at 0.5% [6, 7]. A new longitudinal study utilizing electromyographic analysis (a diagnostic procedure that records the electrical activity of muscle fibers) now offers fresh insights into how injection frequency influences the longevity of muscle paralysis after treatment is discontinued.
Longitudinal Electromyographic Assessment of Short-Interval Dosing
To investigate the long-term physiological impact of frequent chemodenervation, researchers recruited a cohort of 21 Caucasian female participants aged 35 to 60 years. At the start of the study, all participants presented with at least moderate glabellar lines at baseline. The study utilized electromyography (EMG), a diagnostic procedure that records the electrical activity of muscle fibers, to provide an objective measure of muscle function rather than relying solely on visual assessment scales. This methodology allowed the team to track the precise degree of muscle recruitment and paralysis throughout the entire 156-week (3-year) study duration. This objective approach is critical for clinicians because visual scales can be subjective and may not capture the subtle return of subclinical muscle activity that precedes the reappearance of wrinkles.
The experimental protocol was divided into two distinct stages: a 108-week treatment phase followed by a 48-week treatment-free follow-up period to observe the durability of the effect. Participants were randomized into three distinct dosing schedules to compare the impact of injection frequency. Group I received injections every 6 weeks, Group II every 9 weeks, and Group III every 12 weeks. Regardless of the interval, each treatment session was standardized, involving five injections totaling 20 U of onabotulinum toxin A administered directly to the glabellar muscles. This standardization ensured that any observed differences in muscle suppression were attributable to the timing of the doses rather than the volume of toxin administered.
Throughout the 156-week period, the researchers collected serial corrugator electromyographic recordings to monitor the electrical output of the muscles responsible for brow furrowing. These EMG data were subsequently analyzed using linear regression models, a statistical method used to track and predict changes in muscle activity over time by identifying the relationship between the treatment intervals and the resulting electrical suppression. By employing this longitudinal modeling, the study aimed to determine if repeated, short-interval dosing could induce a state of sustained muscle suppression that persists long after the toxin has been metabolized by the body, potentially altering the motor unit's baseline function.
Durable Neuromodulatory Effects and Interval Comparisons
The longitudinal analysis of the electromyographic data demonstrated a consistent, statistically divergent reduction in corrugator muscle activity across all post-treatment time points. This suppression of electrical signals indicates that the repeated administration of onabotulinumtoxinA effectively inhibited muscle recruitment throughout the study period. The researchers noted that maximal suppression of muscle activity occurred at the 108-week mark, which coincided with the conclusion of the active treatment phase. This finding suggests that the cumulative effect of short-interval dosing reaches its peak after two years of consistent intervention, providing a level of muscle relaxation that is maintained even as the toxin is metabolized. For the practicing physician, this implies that the physiological impact of the toxin may be additive over time when dosing intervals are kept short.
To assess the long-term stability of these effects, the authors employed predictive-margins analysis, which is a statistical method used to predict outcomes at specific levels of a covariate, such as time or dosing frequency, while holding other variables constant. This analysis showed sustained suppression of muscle activity from baseline through the full 156 weeks in all treatment groups. While the researchers observed a late increase in electromyographic activity during the 48-week treatment-free follow-up period, the muscle activity levels remained well below pretreatment baselines at the 156-week conclusion. For clinicians, this indicates that the neuromodulatory impact of frequent injections persists for nearly a year after the final dose, suggesting a durable change in muscle function rather than a transient blockade. This long-term suppression suggests that the neuromuscular junction may undergo structural or functional remodeling following prolonged chemodenervation.
When comparing the efficacy of the different dosing schedules, the study found that the frequency of administration influenced the degree of muscle inhibition. The 12-week injection group exhibited higher electromyographic activity relative to the 9-week group, suggesting that the longer interval allowed for greater recovery of muscle function between sessions. Conversely, no meaningful difference in muscle activity was observed between the 6-week group and the 9-week group. This lack of divergence between the two most frequent dosing schedules may imply a ceiling effect for chemodenervation, where increasing the frequency beyond every nine weeks does not yield additional suppression of the corrugator muscles, providing a practical upper limit for aggressive treatment protocols.
Clinical Implications for Maintenance Protocols
The primary objective of this three-year investigation was to determine if prolonged short-interval administration of botulinum neurotoxin A (BoNT-A) induces irreversible paralysis of the glabellar muscles, specifically the corrugator supercilii. Unlike peripheral nerve transection, which typically results in permanent loss of function after 12 to 24 months due to the physical severing of the axon, the long-term physiological impact of chemical denervation via onabotulinumtoxinA has remained poorly defined in clinical literature. The researchers found that prolonged intermittent BoNT-A administration produces a sustained chemodenervation effect (a long-term blockade of neuromuscular transmission) that persists well beyond the cessation of active treatment. This suggests that the cumulative impact of frequent dosing may lead to a highly durable reduction in muscle recruitment, rather than a simple temporary relaxation that dissipates immediately after the toxin is metabolized.
For clinicians managing patients with moderate to severe glabellar lines, these findings suggest a potential shift in long-term maintenance strategies. The study demonstrated that the duration of muscle suppression exceeded the timeframe typically observed with standard clinical dosing intervals, which usually range from three to four months. Even 48 weeks after the final 20 U dose of onabotulinumtoxinA, electromyographic activity remained significantly lower than baseline levels across all three dosing groups (6, 9, and 12-week intervals). This sustained chemodenervation effect indicates that after an intensive two-year treatment phase, patients may require less frequent injections to maintain aesthetic or therapeutic results. While the 12-week group showed higher muscle activity than the 9-week group, the overall persistence of suppression at 156 weeks suggests that the cumulative physiological changes in the motor unit may allow for extended intervals between maintenance sessions without a loss of clinical efficacy, potentially reducing the long-term cost and burden of treatment for the patient.
References
1. Qian H, Shao F, Lenahan C, Shao A, Li Y. Efficacy and Safety of Botulinum Toxin vs. Placebo in Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Psychiatry. 2020. doi:10.3389/fpsyt.2020.603087
2. Meretsky CR, Umali JP, Schiuma AT. A Systematic Review and Comparative Analysis of Botox Treatment in Aesthetic and Therapeutic Applications: Advantages, Disadvantages, and Patient Outcomes. Cureus. 2024. doi:10.7759/cureus.67961
3. Affatato O, Moulin TC, Pisanu C, et al. High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis. Journal of Translational Medicine. 2021. doi:10.1186/s12967-021-02801-w
4. Li X, Sui C, Xia X, Chen X. Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials.. Aesthetic plastic surgery. 2023. doi:10.1007/s00266-022-03018-y
5. Fagien S, Avelar RL, Cox SE, Joseph J, Kaufman‐Janette J, Marcus K. Safety and Duration of Effect of 40-Unit PrabotulinumtoxinA-xvfs for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients: A Phase II, Multicenter, Randomized, Double-Blind, Active-Controlled Trial. Aesthetic Surgery Journal. 2024. doi:10.1093/asj/sjae051
6. Walter U, Albrecht P, Carr W, Hefter H. Systematic Review and Meta‐Analysis of Secondary Treatment Failure and Immunogenicity With Botulinum Neurotoxin A in Multiple Indications. European Journal of Neurology. 2025. doi:10.1111/ene.70289
7. Jankovic J, Carruthers J, Naumann M, et al. Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX®) Treatment from Global Registration Studies across Multiple Indications: A Meta-Analysis. Toxins. 2023. doi:10.3390/toxins15050342
